Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.
Idecabtagene vicleucel (ide-cel) was able to triple progression-free survival and reduce the risk of disease progression or death in a phase 3 trial. Idecabtagene vicleucel (ide-cel; Abecma) from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback